Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intratumoral Heterogeneity on [18F]PSMA-1007 and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Primary Prostate Cancer

NCT06919159 is registered in ClinicalTrials.gov with Jiequn Yu as lead sponsor.

NCT NCT06919159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06919159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intratumoral Heterogeneity on [18F]PSMA-1007 and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Primary Prostate Cancer
Lead sponsor
Jiequn Yu
Phase
Observational
Overall status
Completed
Start date
July 1, 2021
Completion date
November 30, 2022
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

positron emission tomography (pet), prostate cancer (diagnosis), prostate-specific membrane antigen